Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Stephen Newman

Neurology Plainview, NY Medical Doctor

NPI 1578549101 CMS profile 161611

824 Old Country Rd, Plainview, NY 11803

Open in the dashboard

General payments

$489,330

531 records reported · program years 2019–2025

Research payments

$5,137

Paid to them · 2 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$194,197 paid to institutions, not to them · program years 2019–2024

Through program year 2025, Stephen Newman of Plainview, NY is reported in the CMS Open Payments database as having received $489,330 across 531 general payments and $5,137 in research payments paid to them. Separately, studies naming them as principal investigator received $194,197 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $15 1
2022 General $1,100 1
2021 General $96,865 148
2020 General $149,589 133
2020 Research $5,137 2
2019 General $241,762 248

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stephen Newman
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Stephen Newman were reported at $15. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Stephen Newman Neurology median Middle half National median
2019 $241,762 $474 $118–$2,177 $163
2020 $149,589 $367 $82–$2,309 $114
2021 $96,865 $438 $104–$2,547 $132
2022 $1,100 $442 $103–$2,388 $149
2023 $0 $464 $119–$2,312 $160
2024 $0 $468 $119–$2,323 $164
2025 $15 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $152,009 140 payments
  2. Biogen, Inc. $125,645 120 payments
  3. Genzyme Corporation $91,259 60 payments
  4. EMD Serono, Inc. $60,578 66 payments
  5. Celgene Corporation $23,530 26 payments
  6. Genentech USA, Inc. $23,157 28 payments
  7. Novartis Pharma AG $7,309 4 payments
  8. E.R. Squibb & Sons, L.L.C. $3,100 2 payments
  9. Janssen Pharmaceuticals, Inc $1,130 3 payments
  10. Allergan Inc. $407 31 payments
  11. Other $1,207 51 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $397,017 175 payments
  2. Consulting Fee $50,436 14 payments
  3. Travel and Lodging $27,387 69 payments
  4. Food and Beverage $14,352 260 payments
  5. Education $139 13 payments
Products named General payments · program years 2019–2025
  1. TYSABRI $63,179 55 payments
  2. MAYZENT $58,629 62 payments
  3. AUBAGIO Neurology $47,624 29 payments
  4. VUMERITY $33,817 31 payments
  5. TECFIDERA $26,811 25 payments
  6. ZEPOSIA $26,303 26 payments
  7. AUBAGIO Multiple Sclerosis $24,234 18 payments
  8. OCREVUS $23,212 31 payments
  9. Mavenclad $22,746 22 payments
  10. LEMTRADA $19,496 14 payments
  11. Other $73,822 169 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Genentech, Inc. $5,137 2 payments

Records

533 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record